Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients

Liver International

Volumn 27, Issue 2, 2007, Pages 235-239

  Wang, Chia Chi ^a,b   Liu, Chun Jen ^c   Lai, Ming Yang ^c,d   Kao, Jia Horng ^c,d   Chen, Ding Shinn ^c  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b MIN SHENG GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Chronic hepatitis B; HepatitisB e antigen; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; PROTHROMBIN TIME; SEROCONVERSION; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; BLOOD; GENETICS; IMMUNOLOGY; PREDICTION AND FORECASTING; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LINEAR MODELS; LOGISTIC MODELS; MALE; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34247646520     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01418.x     Document Type: Article

References (22)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2: 395-403.
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
3. Chen DS. From hepatitis to hepatoma: Lessons from type B viral hepatitis. Science 1993; 262: 369-70.
4. Kao JH. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003; 46: 400-7.
5. Hoofnagle JH, Dusheiko GM, Seeff LB, et al. Seroconversion from hepatitis e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94: 744-8.
6. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6: 167-72.
7. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005; 25: 472-89.
8. Lok ASF, McMahon BJ. Practice guidelines committee, American association for the study of liver diseases (AASLD). related articles, chronic hepatitis B: Update of recommendation. Hepatology 2004; 39: 857-61.
9. EASL Jury. EASL international consensus conference on hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement. J Hepatol 2003; 38: 533-40.
10. Heijtink RA, Snobl J, Kruining J, et al. Quantitative measurement of HBeAg in chronic hepatitis B: A comparison between a radioimmunoassay, a fluorescence ELISA and a chemiluminescence ELISA. J Med Virol 1995; 47: 245-50.
11. Chien RN, Liaw YF, Akins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian hepatitis lamivudine trial group. Hepatology 1999; 30: 770-4.
12. Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 186-94.
13. Lok AS, Heathcote EJ, Hoofnagle JH, et al. Management of hepatitis B 2000, summary of a workshop. Gastroenterology 2001; 120: 1828-53.
14. Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real time PCR and melting curve analysis. J Hepatol 2004; 41: 659-66.
15. Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carrier. J Infect Dis 2006; 193: 1258-65.
16. Liu CJ, Chen PJ, Lai MY, et al. Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. Liver Int 2006; 26: 949-55.
17. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
18. Kimura T, Rokuhara A, Matsumoto A, et al. New enzyme immunoassay for detection of hepatitis B virus core (HBcAg) and relation between levels of HBcAg and HBV DNA. J Clin Microbiol 2003; 41: 1901-6.
19. Heijtink RA, Janssen HL, Hop WC, et al. Interferon-α therapy in chronic hepatitis B: Early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J Viral Hepatitis 2000; 7: 382-6.
20. Park NH, Shin JW, Park JH, et al. Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B. Viral Hepat 2005; 12: 216-21.
21. Allen MI, Deslauriers M, Andrew CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine clinical investigation group. Hepatology 1998; 27: 1670-7.
22. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-82.